Sanguine Biosciences is accelerating personalized medicine by empowering patients with their healthcare data and facilitating participation in biomedical research. Sanguine actively bridges the gap between patients and researchers through direct-to-patient engagement, in-home collection of fully annotated biospecimens, apheresis product offerings, and a suite of biorepository services. Sanguine has supported translational, clinical, and cell & gene therapy research at 35 of the top 40 global pharmaceutical and biotechnology companies, shortening timelines and validating early-stage results to increase confidence and refine biomarkers in human trials. Four years in a row, Sanguine received the prestigious designation of a “Great Places to Work” company. In 2022, Sanguine was designated #2038 on the Inc. 5000 America’s Fastest Growing Private Companies list and achieved recognition on FORTUNE’s 100 Best Small Workplaces and Best Workplaces in Biopharma. Referenced in over 140 publications, Sanguine studies have appeared in high-impact journals, including Science, Nature, NEJM, Nature Medicine, and Science Translational Medicine. Popular media outlets featuring Sanguine include the Fox News Channel, The Washington Post, Inc.,The Boston Globe, Inc., and many others.